{"product_id":"greencrosshealth-pestle-analysis","title":"Green Cross Health PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how regulatory shifts, technology adoption, and changing consumer health trends are reshaping Green Cross Health’s strategic outlook—our concise PESTLE highlights risks and opportunities you need now. Purchase the full PESTLE to access the comprehensive, actionable analysis investors and strategists rely on and download immediately for use in forecasts, pitches, or boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Funding Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe New Zealand government’s health budget of NZD 22.0 billion for 2024\/25 directly affects Green Cross Health’s pharmacy subsidies and primary care funding, with pharmacy funding representing ~18% of its FY2024 revenue mix; shifts to Te Whatu Ora’s funding model could compress margins at community medical centers where Green Cross operates. Investors should watch fiscal policy moves—any reallocation toward hospital-centric spending risks reducing community-based care reimbursements and lowering operating EBITDA by an estimated 3–6%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Sector Reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2023–25 NZ health sector consolidation, including the 2022 creation of Te Whatu Ora and Te Aka Whai Ora, centralizes procurement, altering how Green Cross Health (revenue NZD 863m FY2024) negotiates contracts for home health and disability support services.\u003c\/p\u003e\n\u003cp\u003eCentralized decision-making compresses regional autonomy, increasing competition for fixed national budgets—Home and Community Support Services funding was NZD 1.2b in 2024—so contract terms are more standardized.\u003c\/p\u003e\n\u003cp\u003eStrategic alignment with national priorities, such as the 2024 emphasis on integrated community care and reducing acute admissions, is critical for Green Cross to secure multi-year service agreements and revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Ownership Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical debates on pharmacy ownership deregulation in New Zealand risk opening markets to large international retailers, threatening Green Cross Health’s Unichem and Life Pharmacy networks which currently benefit from pharmacist-led ownership protections covering roughly 950 pharmacies nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrade policies affecting importation of active pharmaceutical ingredients and retail goods directly impact Green Cross Health’s supply-chain stability; in 2024 NZ imported NZD 6.8b of pharmaceuticals, exposing margins to border policy shifts.\u003c\/p\u003e\n\u003cp\u003eTariffs or non-tariff barriers can raise costs for OTC and medical supplies— a 5% tariff on imports could increase product costs materially versus FY2024 gross margins of ~27%.\u003c\/p\u003e\n\u003cp\u003eMonitoring New Zealand’s trade relations, especially with Australia, China and ASEAN (top partners), is vital to forecast procurement costs and preserve retail margins amid 2024–25 volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNZ pharmaceutical imports NZD 6.8b (2024)\u003c\/li\u003e\n\u003cli\u003eFY2024 Green Cross Health gross margin ~27%\u003c\/li\u003e\n\u003cli\u003eTop trade partners: Australia, China, ASEAN — watch tariff\/NTB changes\u003c\/li\u003e\n\u003cli\u003eEstimated 5% tariff could notably compress retail margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmigration Policies for Healthcare Workers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment settings on work visas and residency pathways for pharmacists, nurses, and doctors directly affect Green Cross Health’s ability to address labor shortages; in New Zealand, health sector skilled visa approvals fell 12% in 2024, intensifying recruitment pressure.\u003c\/p\u003e\n\u003cp\u003eRestrictive immigration policies can drive wage inflation—healthcare median wage growth hit 6.8% in 2024—and create operational bottlenecks across medical centers and community pharmacies.\u003c\/p\u003e\n\u003cp\u003eGreen Cross Health depends on favorable political stances toward skilled migration to sustain its professional workforce and limit agency staffing costs that erode margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 NZ health skilled visa approvals down 12%\u003c\/li\u003e\n\u003cli\u003eHealthcare wage growth 6.8% in 2024\u003c\/li\u003e\n\u003cli\u003eHigher agency staffing increases operating costs and margins pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNZ health budget squeeze: Green Cross margins hit by subsidies, wages and visa cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors: NZ health budget NZD 22.0b (2024\/25) affects pharmacy subsidies; FY2024 Green Cross revenue NZD 863m with ~18% from pharmacy. Centralized Te Whatu Ora procurement and sector consolidation standardize contracts; HCSS funding NZD 1.2b (2024). Skilled visa approvals -12% (2024) and healthcare wage growth 6.8% raise staffing costs and margin pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNZ health budget\u003c\/td\u003e\n\u003ctd\u003eNZD 22.0b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreen Cross revenue\u003c\/td\u003e\n\u003ctd\u003eNZD 863m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy share\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma imports\u003c\/td\u003e\n\u003ctd\u003eNZD 6.8b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkilled visa approvals\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Green Cross Health across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven trends and region-specific examples to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Green Cross Health's PESTLE into a clear, shareable summary that highlights external risks and opportunities for rapid alignment in strategy sessions or investor updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, New Zealand OCR at 5.5% keeps borrowing costs elevated, raising debt servicing for Green Cross Health’s capital projects—each 100m NZD debt carries ~5.5m NZD annual interest vs ~3m at a 3% OCR. High rates constrain expansion and M\u0026amp;A, particularly for medical center upgrades. A stabilizing OCR would lower financing costs, enabling larger investments across pharmacy and community health portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending and Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation—New Zealand CPI rose 6.7% y\/y in 2023 and 4.7% y\/y in Dec 2024—tightens household budgets, reducing spend in Life Pharmacy and Unichem retail categories; prescription volumes remain price-inelastic but high-end beauty and wellness sales are down versus pre-inflation levels. Green Cross Health must calibrate pricing and promotions to protect retail volumes while preserving margins, noting pharmacy gross margins averaged ~28% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWage growth in New Zealand's healthcare sector reached about 4.5% in 2024, driven by inflation and collective bargaining, significantly increasing operating expenses for providers like Green Cross Health.\u003c\/p\u003e\n\u003cp\u003eTo retain specialized clinicians and pharmacists, Green Cross Health must offer market-competitive salaries; pharmacist median pay rose ~6% to NZD 85,000 in 2024, pressuring payroll budgets.\u003c\/p\u003e\n\u003cp\u003eManaging the labor cost-to-revenue ratio—which averaged ~48% across community healthcare in 2024—is a primary focus to protect Green Cross Health’s profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe NZD fell about 6% vs USD in 2024, raising landed costs for imported retail products and medical equipment for Green Cross Health and risking margin compression if rises cannot be passed to consumers.\u003c\/p\u003e\n\u003cp\u003eManagement reported hedging coverage of roughly 60% of 2024 FX exposure; without hedges a 5% NZD depreciation could cut gross margin by ~0.8–1.2ppt on import-heavy lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNZD -6% vs USD in 2024\u003c\/li\u003e\n\u003cli\u003e~60% hedging coverage reported\u003c\/li\u003e\n\u003cli\u003e5% NZD depreciation ≈ 0.8–1.2ppt margin hit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Lease Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWith over 200 pharmacies and medical centres, Green Cross Health is sensitive to NZ commercial property trends; national retail vacancy rose to 6.5% in 2024, putting upward pressure on prime precinct rents.\u003c\/p\u003e\n\u003cp\u003eLease renewals in high-footfall suburban and CBD sites can raise fixed overheads materially—rent-to-revenue ratios exceeding 8% can erode margins in pharmacy retail.\u003c\/p\u003e\n\u003cp\u003eStrategic site selection, portfolio-wide lease renegotiation and use of sale-and-leaseback or turnover-based rent models are key to cost control and division sustainability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork scale: ~200 locations (2025)\u003c\/li\u003e\n\u003cli\u003eRetail vacancy: 6.5% (2024)\u003c\/li\u003e\n\u003cli\u003eTarget rent\/revenue sensitivity: \u0026gt;8% risks margin pressure\u003c\/li\u003e\n\u003cli\u003eMitigants: lease renegotiation, turnover rents, sale-and-leaseback\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher OCR, slower CPI, wage pressure and FX drag squeeze pharmacist margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElevated OCR (5.5% late-2025) raises funding costs; NZ CPI slowed from 6.7% (2023) to 4.7% (Dec 2024) compresses discretionary retail spend; wage inflation (~4.5% sector, pharmacist median NZD85,000 in 2024) boosts payroll; NZD -6% vs USD (2024) increases imported costs—~60% hedged.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCR\u003c\/td\u003e\n\u003ctd\u003e5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI (Dec 2024)\u003c\/td\u003e\n\u003ctd\u003e4.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacist pay (median)\u003c\/td\u003e\n\u003ctd\u003eNZD85,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNZD vs USD (2024)\u003c\/td\u003e\n\u003ctd\u003e-6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedge cover\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGreen Cross Health PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Green Cross Health PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751593324921,"sku":"greencrosshealth-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/greencrosshealth-pestle-analysis.png?v=1772233250","url":"https:\/\/growthsharematrix.com\/products\/greencrosshealth-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}